Midostaurin in advanced systemic mastocytosis

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2605-2607

  Chandesris, Marie Olivia ^a   Damaj, Gandhi ^b   Canioni, Danielle ^c   Brouzes, Chantal ^c   Lhermitte, Ludovic ^c   Hanssens, Katia ^d   Frenzel, Laurent ^c   Cherquaoui, Zoubair ^c   Durieu, Isabelle ^e   Durupt, Stéphane ^e   Gyan, Emmanuel ^f   Beyne Rauzy, Odille ^g   Launay, David ^h   Faure, Cyril ⁱ   Hamidou, Mohamed ^j   Besnard, Sophie ^k   Diouf, Momar ^l   Schiffmann, Aurélie ^m   Niault, Mathilde ⁿ   Jeandel, Pierre Yves ^o   Ranta, Dana ^p   Gressin, Remi ^q   Chantepie, Sylvain ^b   Barete, Stéphane ^r   Dubreuil, Patrice ^d   Bourget, Philippe ^c   Lortholary, Olivier ^c   Hermine, Olivier ^s   more..

^a French Reference Center for Mastocytosis   (France)

^b Normandy School of Medicine   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g CHU PURPAN   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ Vesoul Regional University Hospital   (France)

^j HÔTEL DIEU   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m HÔPITAL SAINT ELOI   (France)

ⁿ Quimper ICU   (France)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^p UNIVERSITY HOSPITAL OF NANCY   (France)

^q GRENOBLE UNIVERSITY HOSPITAL   (France)

^r HÔPITAL TENON   (France)

^s IMAGINE INSTITUTE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; MIDOSTAURIN; 4'-N-BENZOYLSTAUROSPORINE; ANTINEOPLASTIC AGENT; STAUROSPORINE;

AGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFORMED CONSENT; LETTER; LYMPHOCYTOPENIA; MAST CELL LEUKEMIA; MORTALITY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; STOMACH DISCOMFORT; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CONTROLLED CLINICAL TRIAL; MASTOCYTOSIS, SYSTEMIC; MULTIVARIATE ANALYSIS; ONSET AGE; SURVIVAL RATE;

AGE OF ONSET; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MASTOCYTOSIS, SYSTEMIC; MULTIVARIATE ANALYSIS; STAUROSPORINE; SURVIVAL RATE;

EID: 84976480011     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1515403     Document Type: Letter

References (4)

1. Horny HP, Metcalfe DD, Bennett JM. Mastocytosis. In: Swerd-low SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008: 53-63.
2. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
3. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721-4.
4. Gotlib J, Pardanani A, Akin C, et al. International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic masto-cytosis. Blood 2013;121:2393-401.